Protect Act This bill duplicates certain requirements for private health insurance plans with respect to preexisting conditions, enrollment eligibility, genetic testing, and discrimination based on health-related factors.
COVID-19 Supply Chain Resiliency Act of 2021 This bill establishes the Office of COVID-19 Supply Chain Resiliency to identify and address supply chain issues related to the COVID-19 (i.e., coronavirus disease 2019) pandemic. Specifically, the office must establish a national strategy to address identified supply chain issues related to the pandemic, serve as a central point of contact for and provide technical assistance to entities dealing with these issues, and develop legislative recommendations to strengthen critical supply chains for pandemics. The office shall cease to exist 18 months after the COVID-19 public health emergency (and any renewal thereof) is terminated.
This joint resolution nullifies the action of the District of Columbia Council in approving the Minor Consent for Vaccinations Amendment Act of 2020, enacted by the council on December 23, 2020, and transmitted on February 4, 2021 [ sic ], to Congress pursuant to the District of Columbia Home Rule Act. The act authorizes a minor, 11 years of age or older, to consent to receive a vaccine if the minor is capable of meeting the informed consent standard and the vaccine is recommended by the United States Advisory Committee on Immunization Practices and will be provided in accordance with its recommended immunization schedule.
This resolution recognizes Black History Month as an opportunity to reflect on U.S. history and to commemorate the contributions of African Americans. It calls for the United States to (1) honor the contribution of pioneers who helped to ensure its legacy; and (2) move forward as a nation "indivisible, with liberty and justice for all."
Dignity for Aborted Children Act This bill sets out requirements for the disposition of human fetal tissue from an abortion. Specifically, it requires abortion providers to obtain a patient's informed consent for one of two specified methods of disposition. First, patients may choose to retain possession of the tissue. A patient may choose to transfer the tissue to an entity that provides interment or cremation services. Second, the patient may elect to release the tissue to the provider. Providers must ensure any tissue released to them is interred or cremated within seven days of the procedure in a manner consistent with state law regarding the disposal of human remains. Abortion providers must report annually about these requirements and other specified information. The bill provides civil or criminal penalties for violations of disposal, informed consent, and reporting requirements.
Parental Notification and Intervention Act This bill restricts the performance of an abortion on an unemancipated minor under 18 years of age. Specifically, it prohibits a person or organization from performing, facilitating, or assisting with an abortion on an unemancipated minor without first complying with certain requirements, including parental notification and a 96-hour waiting period. It establishes penalties—a fine, up to one year in prison, or both—for each willful violation. A parent who is required to be notified of an abortion of an unemancipated minor may sue in federal court to prohibit the abortion. Parental notification requirements may be waived in a medical emergency or in a case of physical abuse.
Protection of Women and Girls in Sports Act of 2021 This bill makes it a violation of federal law for a recipient of federal funds who operates, sponsors, or facilitates athletic programs or activities to permit a person whose sex is male to participate in an athletic program or activity that is designated for women or girls. The bill specifies that sex shall be recognized based solely on a person's reproductive biology and genetics at birth.
This bill expedites the approval process for renewable fuels under the renewable fuel standard (RFS) program. The existing RFS program requires transportation fuel to contain a minimum volume of renewable fuel. Producers must register renewable fuels under the program. The bill considers an application to register a renewable fuel under the RFS program to be approved by the Environmental Protection Agency (EPA) if the fuel has been approved under any state renewable fuel program. It also establishes a deadline for the EPA to make a decision on any pending application for a renewable fuel that has not yet been approved under any state program. In addition, the bill establishes deadlines for the EPA to make decisions on pending pathway petitions by producers to register biofuels. If the EPA does not make decisions on the petitions by the deadlines, then petitions are automatically approved.
Public Health Emergency Production Act of 2021 This bill modifies funding, administration, and reporting related to the Defense Production Act of 1950. That act confers upon the President a broad set of authorities to influence domestic industry to secure essential materials and goods needed for the national defense. Specifically, the bill eliminates a requirement to transfer any balance in excess of $750 million from the Defense Production Act Fund to the General Fund of the Department of the Treasury. In addition, the Department of Health and Human Services (HHS) must require companies to prioritize fulfilling federal contracts or orders necessary for pandemic preparedness and response if HHS finds that the material being procured is essential to the public health and cannot be adequately sourced through normal distribution channels. HHS must also establish, within the Office of the Assistant Secretary for Preparedness and Response, an office responsible for Defense Production Act of 1950 activities. Additionally, staff may rotate between the Office of the Deputy Assistant Secretary of Defense for Industrial Policy and specified components of HHS. Furthermore, the Defense Production Act Committee must report monthly about the use of Defense Production Act of 1950 authorities during the COVID-19 (i.e., coronavirus disease 2019) emergency.
Adopt the Greenhouse gases, Regulated Emissions, and Energy use in Transportation model Act or the Adopt GREET Act This bill requires the Environmental Protection Agency (EPA) to update the methodology used in life-cycle analyses of greenhouse gas emissions that result from the production and use of corn-based ethanol and biodiesel fuel. The EPA must update its methodology within 90 days and every five years thereafter. In the first update, the EPA must adopt the most recent Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (commonly referred to as the GREET model) developed by Argonne National Laboratory.
Effective Drug Control Strategy Act of 2021 This bill requires the Office of National Drug Control Policy to (1) evaluate the effectiveness of all federally funded activities aimed at reducing the demand for illegal drugs, and (2) publish annually a complete list of all drug control grant programs.
Support And Value Expectant Moms and Babies Act of 2021 or the SAVE Moms and Babies Act of 2021 This bill prohibits the Food and Drug Administration (FDA) from approving any new drug (either as a brand-name drug or a generic) intended to terminate a pregnancy and imposes additional restrictions on such drugs that are already approved. Under the bill, an already-approved drug intended to terminate a pregnancy may be dispensed to a patient only with a prescription. Furthermore, the FDA may not approve any labeling change that would authorize (1) using the drug after 70 days of gestation, or (2) dispensing the drug by any means other than in-person administration by the prescribing health care practitioner. The FDA must also impose additional restrictions on such already-approved drugs, including by (1) requiring the prescribing health care practitioner to receive a special certification, (2) prohibiting the practitioner to also act as the dispensing pharmacist, and (3) requiring the practitioner to have the ability to provide surgical intervention to the patient. The bill also rescinds any investigational use exemption already granted to such a drug if the bill would have prohibited the FDA from granting the exemption. (Currently, the FDA may grant an exemption to certain market approval requirements if a drug is intended solely for use in safety and effectiveness investigations.)
